Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-04-02 M&A Activity
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma completes the acquisition of Valeritas
M&A Activity Classification · 100% confidence The document is a formal company announcement regarding the completion of an acquisition of Valeritas Holdings, Inc. by Zealand Pharma. Since it details a merger/acquisition transaction, it falls under the M&A Activity category.
2020-04-02 English
M&A Activity 2020
M&A Activity Classification · 99% confidence The document is titled "Company announcement – No. 15 / 2020" and details the completion of an acquisition (Zealand Pharma acquires Valeritas). This is a specific corporate action announcement, not a comprehensive periodic report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a material event disclosure. Since it is a specific corporate announcement that doesn't fit the highly specific categories like DIV, CAP, or TAR, it falls best under the general regulatory announcement category, RNS, as it is a press release detailing a significant corporate event. The document length is moderate (5829 chars), and it is not merely announcing the publication of another document, thus RPA is not the best fit.
2020-04-02 English
Zealand Pharma provides business update related to current COVID-19 situation
AGM Information Classification · 95% confidence The document is a company announcement titled 'Zealand Pharma provides business update related to current COVID-19 situation'. It covers multiple topics including R&D progress, NDA submission, commercial operations, a private placement of shares, and logistics for an upcoming AGM. Because the document is a general corporate update that does not fit into a single specific category like 'Earnings Release' or 'Annual Report', and it explicitly includes an 'Attachment' section at the end with a link to the full report, it is classified as a Report Publication Announcement (RPA) under the provided filing definitions.
2020-04-02 English
Regulatory Filings 2020
Regulatory Filings Classification · 99% confidence The document is a business update issued on April 2, 2020, detailing R&D progress, an NDA submission, financing, and importantly, announcing that the Annual General Meeting (AGM) will be hosted virtually. The text explicitly mentions: 'Zealand Pharma's Annual General Meeting will be hosted virtually, encouraging shareholders to participate via webcast transmission instead of attending in person' and 'Zealand intends to conduct its Annual General Meeting later today, April 2, 2020...'. Since the primary focus of the announcement, besides the business update, is the logistics and execution of the AGM, the most specific classification is AGM-R (AGM Information). While it contains elements of an Earnings Release (ER) or Management Report (MDA) due to the business update, the explicit mention and focus on the AGM logistics strongly points to AGM-R.
2020-04-02 English
Correction: Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly identifies a member of the Board of Directors (Jens Peter Stenvang) purchasing shares of the company (Zealand Pharma A/S). This is a classic insider trading disclosure, which falls under the 'Director's Dealing' category.
2020-04-01 English
Correction: Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). While the document mentions that the details are in an attached file, the primary purpose of this specific text is to report insider dealings as required by market regulations. According to the filing definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2020-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.